Liesbet De Cock

Liesbet De Cock holds a MSc Biology/Biotechnology from the University of Ghent, Belgium. She worked for four years as Scientific Collaborator at the Institute of Public Health (Sciensano) in Brussels. From 2005 to 2022, she worked in GlaxoSmithKline (GSK), starting in the GSK Vaccines Unit, joining the Epidemiology team moving later to the Clinical Operations team taking roles of increasing responsibility over 10 years. She has been heading the Strategic Portfolio Management team reporting on the progress and recommending on the investments of R&D Vaccines portfolio. After an assignment in Business Development leading due diligences and exploring new partnerships, she joined the Decision Sciences team in the GSK Pharma Unit in London, assigned to the Infectious Diseases and Specialty, piloting advanced methodologies enabling sound decision making. Later, she joined the new GSK Global Head Unit being set up.

Since Astrivax’ spin off from the University of Leuven in 2022, she led the vaccine development bringing two vaccines candidates into First Time in Human. Since July 2024, she joined EDCTP3 JU as Head of Unit, Scientific Operations.